Developing protein-based vaccines to prevent enterovirus infections
Enteroviruses can cause illnesses ranging from mild infections to myocarditis, meningitis and paralysis. Most lack vaccines, while conventional vaccine development is hindered by difficulties growing the viruses and manufacturing them safely.
Velocin develops protein-based enterovirus vaccines using engineered particles that mimic viruses without carrying genetic material. Its first vaccine is in preclinical development, aiming to prevent disease without growing the infectious pathogen during production.
What stands out about Velocin
A peer-reviewed study of the engineered CVB1 vaccine reported neutralizing antibodies and protection against viral challenge in mice.
The engineered enterovirus-particle invention was transferred to Innofend Oy; the paper identifies its patent application FI 20253217.
Joined Health Incubator Helsinki in 2025, receiving tailored business-development support and access to its health-sector network.
Co-founder Minna Hankaniemi is an adjunct professor whose vaccine research underpins the engineered enterovirus-particle platform.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.